News

According to NeuroGenetic the funds will be used for the development of their lead candidate, NGP 555 used to prevent AD and initiate clinical trials. NGP 555, a

Eylea (aflibercept) Injection is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) which is a major cause of blindness in older adults. The injection secured

Xeomin was approved by the US FDA in July 2010 for the treatment of cervical dystonia in adults. The drug is believed to decrease the severity of abnormal

According to the company, its Investigational New Drug Application (IND) is now open for a Phase 2 study that follows a review of PBT2 data by the FDA

ACH-1625, a once-daily HCV protease inhibitor and an open chain, non-covalent NS3 protease inhibitor, is currently being evaluated in a Phase 2 clinical trial as a treatment for

Bepotastine besilate is a non-sedating, highly selective antagonist of the histamine H1 receptor, approved in Japan for systemic use in the treatment of allergic rhinitis. The Phase 2

The trial ‘ReACT Study’ will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopepimut in patients with newly diagnosed EGFRvIII-expressing glioblastoma (GB). Rindopepimut is an

As per the agreement, Ironwood will develop and commercialize Bionomics’ investigational anti-anxiety compound BNC210 and other related compounds. Under the collaboration, Bionomics may receive up to $345m in

The company will also adopt Cegedim Relationship Management’s OneKey, the global healthcare professional (HCP) database, and insightful Mobile Intelligence Analytics. Pharmaceutical CRM Solution is believed to deliver Operational